valsartan has been researched along with furosemide in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.33) | 18.2507 |
| 2000's | 5 (16.67) | 29.6817 |
| 2010's | 18 (60.00) | 24.3611 |
| 2020's | 6 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Faller, B; Wohnsland, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, X; Lin, X; Skolnik, S; Wang, J | 1 |
| Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
| Honda, K; Izumi, T; Miyaji, Y; Nakayama, S; Okazaki, O; Okudaira, N; Shiosakai, K; Sugiyama, D; Suzuki, W; Takakusa, H; Watanabe, A | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bindschedler, M; de Gasparo, M; Degen, P; Flesch, G; Preiswerk, G | 1 |
| Azizi, M; Bissery, A; Lamarre-Cliche, M; Ménard, J | 1 |
| McKinley, MJ | 1 |
| Feng, S; Guo, Z; Han, P; Li, J; Ma, Y; Zhao, X | 1 |
| Chen, X; Gao, X; Lu, G; Luo, C; Luo, J; Peng, L; Zuo, Z | 1 |
| Ayalasomayajula, S; Chen, F; Langenickel, TH; Pal, P; Schuehly, U; Sunkara, G; Zhou, W | 1 |
| Claggett, B; Desai, AS; Kachadourian, J; Lefkowitz, M; McMurray, JJV; Packer, M; Rouleau, J; Shi, V; Solomon, SD; Swedberg, K; Vardeny, O; Zile, MR | 1 |
| Auria, F; Bonadies, D; Carrizzo, A; Ciccarelli, M; Citro, R; De Angelis, E; Galasso, G; Gigantino, A; Iaccarino, G; Loria, F; Polito, MV; Rispoli, A; Silverio, A; Vecchione, C; Vitulano, G | 1 |
| Aboul-Enein, HY; Ali, I; ALOthman, ZA; Alsheetan, KM | 1 |
| Beavers, JC; Orvin, NJ; Russell, SD | 1 |
| Alhan, A; Altay, H; Altın, C; Ataş, AE; Baş, MM; Çakmak, HA; Demirkan, B; Dereli, S; Durakoğlugil, ME; Ekici, B; Fahri Erkan, A; Karavelioğlu, Y; Kılıçaslan, B; Kılıçaslan, F; Kıvrak, T; Küçük, M; Olgun, FE; Özkan, H; Şabanoğlu, C; Tengiz, İ; Yaman, M; Yenerçağ, M; Yiğit, Z; Zoghi, M | 1 |
| Chatur, S; Claggett, BL; Desai, AS; Jering, K; Lefkowitz, M; McMurray, JJV; Pfeffer, MA; Solomon, SD; Vaduganathan, M; Vardeny, O | 1 |
| Aoki, J; Asami, M; Horiuchi, Y; Ishizawa, T; Kawakami, T; Komiyama, K; Nakajima, M; Nakase, M; Nonaka, H; Sekiguchi, M; Setoguchi, N; Tanabe, K; Tanaka, J; Watanabe, Y; Yahagi, K; Yuzawa, H | 1 |
2 review(s) available for valsartan and furosemide
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
5 trial(s) available for valsartan and furosemide
| Article | Year |
|---|---|
Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide.
Topics: Administration, Oral; Adult; Angiotensin II; Antihypertensive Agents; Area Under Curve; Blood Pressure; Cross-Over Studies; Diuretics; Drug Synergism; Furosemide; Humans; Male; Middle Aged; Renin; Tetrazoles; Valine; Valsartan | 1997 |
Integrating drug pharmacokinetics for phenotyping individual renin response to angiotensin II blockade in humans.
Topics: Administration, Oral; Adolescent; Adult; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Area Under Curve; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cross-Over Studies; Diet, Sodium-Restricted; Diuretics; Dose-Response Relationship, Drug; Double-Blind Method; Furosemide; Genetic Variation; Humans; Juxtaglomerular Apparatus; Male; Renin; Renin-Angiotensin System; Reproducibility of Results; Tetrazoles; Valine; Valsartan | 2004 |
Effect of the angiotensin receptor-neprilysin inhibitor sacubitril/valsartan on the pharmacokinetics and pharmacodynamics of a single dose of furosemide.
Topics: Adolescent; Adult; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Trials as Topic; Diuresis; Diuretics; Drug Combinations; Drug Interactions; Female; Furosemide; Healthy Volunteers; Humans; Male; Middle Aged; Natriuresis; Randomized Controlled Trials as Topic; Tetrazoles; Valsartan; Young Adult | 2018 |
Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biological Availability; Biphenyl Compounds; Dose-Response Relationship, Drug; Drug Combinations; Drug Monitoring; Enalapril; Female; Furosemide; Heart Failure; Humans; Male; Medication Therapy Management; Middle Aged; Outcome Assessment, Health Care; Sodium Potassium Chloride Symporter Inhibitors; Stroke Volume; Tetrazoles; Valsartan | 2019 |
Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON-HF trial.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diuretics; Drug Combinations; Furosemide; Heart Failure; Humans; Sodium Potassium Chloride Symporter Inhibitors; Stroke Volume; Tetrazoles; Valsartan | 2023 |
23 other study(ies) available for valsartan and furosemide
| Article | Year |
|---|---|
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
Topics: Alkanes; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; Membranes, Artificial; Octanols; Permeability; Pharmaceutical Preparations; Solubility; Water | 2001 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity | 2011 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
Topics: Glutathione; Pharmacology; Sulfur Radioisotopes | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Adaptive appetites for salted and unsalted food in rats: differential effects of sodium depletion, DOCA, and dehydration.
Topics: Acetazolamide; Adaptation, Psychological; Animal Feed; Animals; Appetite; Behavior, Animal; Dehydration; Desoxycorticosterone; Diuretics; Eating; Furosemide; Homeostasis; Male; Mineralocorticoids; Models, Animal; Rats; Rats, Sprague-Dawley; Sodium; Sodium Chloride, Dietary; Tetrazoles; Valine; Valsartan | 2013 |
[Simultaneous determination of four drugs for kidney diseases in urine by high performance liquid chromatography].
Topics: Chromatography, High Pressure Liquid; Enalapril; Furosemide; Humans; Kidney Diseases; Triamterene; Valsartan | 2015 |
Hydrochlorothiazide modulates ischemic heart failure-induced cardiac remodeling via inhibiting angiotensin II type 1 receptor pathway in rats.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Cells, Cultured; Disease Models, Animal; Diuretics; Fibroblasts; Fibrosis; Furosemide; Heart Failure; Heart Ventricles; Hydrochlorothiazide; Male; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Recovery of Function; Signal Transduction; Smad2 Protein; Stroke Volume; Transforming Growth Factor beta1; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2017 |
Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Arterial Pressure; Biphenyl Compounds; Cardiotonic Agents; Case-Control Studies; Diuretics; Drug Combinations; Echocardiography; Female; Furosemide; Heart; Heart Failure; Humans; Kidney; Kidney Function Tests; Male; Middle Aged; Patient Readmission; Regression Analysis; Retrospective Studies; Stroke Volume; Survival Analysis; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left | 2020 |
Applications of shun shell column and nanocomposite sorbent for analysis of eleven anti-hypertensive in human plasma.
Topics: Adsorption; Antihypertensive Agents; Chromatography, High Pressure Liquid; Diltiazem; Furosemide; Humans; Hydrochlorothiazide; Irbesartan; Iron; Labetalol; Limit of Detection; Losartan; Metal Nanoparticles; Methyldopa; Nanocomposites; Polyvinyl Alcohol; Prazosin; Propranolol; Reproducibility of Results; Solid Phase Microextraction; Spironolactone; Valsartan | 2020 |
Acute Diuretic-Sparing Effects of Sacubitril-Valsartan: Staying in the Loop.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Diuretics; Drug Combinations; Furosemide; Heart Failure; Humans; Retrospective Studies; Sodium Potassium Chloride Symporter Inhibitors; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left | 2022 |
Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR).
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diuretics; Drug Combinations; Female; Furosemide; Glycated Hemoglobin; Heart Failure; Humans; Hypertension; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Retrospective Studies; Stroke Volume; Turkey; Valsartan; Ventricular Dysfunction, Left | 2021 |
Diuretic and renal effects of angiotensin receptor-neprilysin inhibitor in patients hospitalized for acute heart failure.
Topics: Antihypertensive Agents; Diuretics; Drug Combinations; Furosemide; Heart Failure; Humans; Kidney; Neprilysin; Stroke Volume; Tetrazoles; Valsartan | 2023 |